GM1 inhibits amyloid β-protein-induced cytokine release

Neurochemical Research

Volumn 24, Issue 2, 1999, Pages 219-226

  Ariga, Toshio ^a   Yu, Robert K ^b  

^a EISAI CO LTD   (Japan)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Cytokines; GM1 ganglioside; Interleukin 1 , interleukin 6; Tumor necrosis factor

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CYTOKINE; GANGLIOSIDE; GANGLIOSIDE GM1; GANGLIOSIDE GM3; GANGLIOTETRAOSYLCERAMIDE; GLOBOSIDE; GLYCOSPHINGOLIPID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOSYLCERAMIDE; LIPOPOLYSACCHARIDE; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; CELL STIMULATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; MEMBRANE TRANSPORT; MONOCYTE; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; CELL LINE; G(M1) GANGLIOSIDE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032903798     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022557920150     Document Type: Article

References (52)

1. IUPAC-IUB Commission on Biochemical Nomenclature. 1976. The nomenclature of lipids. Lipids, 12, 455-463.
2. Svennerholm, L. 1964. The gangliosides. J. Lipid Res. 5, 145-153.
3. Braak, H., Braak, E., Grundke-Iqbal, I., and Iqbal, K. 1986. Occurrence of neurophil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillar tangles and neuritic plaques. Neurosci. Lett. 65, 351-355.
4. Selkoe, D.J. 1993. Physiological production of the β-amyloid protein and the mechanism of Alzheimer disease. Trends Neurosci. 16, 403-409.
5. Selkoe, D.J. 1996. Amyloid β-protein and genetics of Alzheimer's disease. J. Biol. Chem. 271, 18295-18298.
6. Pike, C.J., Vaughan, P.J., Cunnigham, D.D., and Vitman, C.W. 1996. Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by β-amyloid in vitro. J. Neurochem. 66, 1374-1382.
7. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuutek, H., and Riederer, P. 1995. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 202, 17-20.
8. Lieb, K., Fiebich, B.L., Schaller, H., Berger, M., and Bauer, I. 1996. Interleukin-1β and tumor necrosis factor-α induce expression of α1-anti-chymotrypsin in human astrocytoma cells by activation of nuclear factor-B. J. Neurochem. 67, 2039-2044.
9. Griffin, W.S.T., Stanley, L.C., Ling, C., White, L., Macleod, V., Peerott. L.J., White III., C.L., and Araoz, C. 1989. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A.86, 7611-7615.
10. Araujo, D.M., and Lapchak, P.A. 1994. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's disease: Selective effects on specific interleukins and interleukin receptors. Neuroscience 61, 745-764.
11. Gitter, B.D., Cox, L.M., Rydel. R.E., and May, P.C. 1993. Amyloid peptide potentates cytokine secretion by interleukin-1β-activated human astrocytoma cells. Proc. Natl. Acad. Sc. U.S.A. 92, 10738-10741.
12. Ledeen, R.W. 1989. Biosynthesis, metabolism, and biological effects of gangliosides. In: Neurobiology and Glycoconjugates. Margolis, R.U., and Margolis, R.K. eds., New York, Plenum, pp. 43-83.
13. Yu, R.K. 1994. Developmental regulation of ganglioside metabolism. Progr. Brain Res. 102,33-44.
14. Kracun, I., Kalanj, S., Talan-Hranilovic, J., and Cosovic, C. 1992. Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 20, 433-438.
15. Yanagisawa, K., Odaka, A., Suzuki, N., and Ihara, Y. 1995. GM1 ganglioside-bound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimer's disease. Nature Medicine, 1, 1062-1066.
16. Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Kouno, T., and Tada, K. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1) Int. J. Cancer. 26, 171-176.
17. Kastelic, T., Schnyder, J., Leutwiler, A., Trber, R., Streit, B., Niggli, H., MacKenzie, A., and Cheneval, D. 1996. Induction of rapid IL-1β mRNA degradation in THP-1 cells mediated through the AU-rich region in the 3'UTR by a radicicol analogue. Cytokine 8, 751-761.
18. Ariga, T., Tao, R.V., Lee, B.-C., Yamawaki, M., Yoshino, H., Scarsdale, N.J., Kasama, T., Kushi, Y., and Yu, R. K. 1994. Glycolipid composition of human cataractous lenses. J. Biol. Chem. 269, 2667-2675.
19. Kasai, N., Silerud, L.O., and Yu, R.K. 1982. A convenient method for the preparation of asialo-GM1 Lipids 17, 107-110.
20. Lorton, D., Kocsis, J-M., King, L., Madden, K., and Brunden, K.R. 1996. β-Amyloid induces increased release of interleukin-1 from lipopolysaccharide-activated human monocytes. J. Neuroimmunol. 67, 21-29.
21. Maggio, B., Ariga, T., Sturtevant, J.M., and Yu, R.K. 1985. Thermotrophic behavior of glycosphingolipids in aqueous dispersions. Biochemistry 24, 1084-1092.
22. MacKenzie, C.R., Hirama, T., Lee, K.K., Altman, E., and Young, N.N. 1997. Quantitative analysis of bacterial toxin affinity and specificity for glycolipid receptors by surface resonance. J. Biol. Chem. 272, 5533-5538.
23. Hertel, C., Hauser, N., Schubenel, R., Seiheimer, B., and Kemp, J.A. 1996. β-Amyloid-induced cell toxicity. Enhancement of 3- (4,5-dimethylthiazol-2-y)-2,5-diphenyltetrazolium bromide-dependent cell death. J. Neurochem. 67, 272-276.
24. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagoplan, S., Johnson-Wood, K., Khan, K., Lee, M., Lelbowitz, P., Lieberburg, I., Little, S., Masliah, E., McConloque, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Schenk, D., Seubert, P., Snyder, B., Sorlanno, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717V β-amyloid precursor protein. Nature 373, 523-527.
25. Pike, C.J., Walencewicz, A.J., Galbe, C.G., and Cotoman, C.W. 1991. In aging of amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
26. Lorenzo, J,-Y., and Yankner, B.A. 1994. β-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 94, 12243-12247.
27. Hensley, K., Carney, J.M., Mattson, M.P., Aksennova, M., Harris, M., Wu, J.F., Floyd, R., and Butterfield, D.A. 1994. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 91, 3270-3274.
28. Terzi, E., Holtzemann, G., and Seelig, J. 1998. Interaction of Alzheimer β-amyloid peptide (1-40) with lipid membranes. Biochemistry 35, 14845-14852.
29. Hertel, C., Terzi, E., Hauser, N., Jakob-Rotne, R., Seelig, J., and Kemp, J.A. 1997. Inhibition of the electrostatic interaction between β-amyloid peptide and membranes prevents β-amyloid-induced toxicity. Proc. Natl. Acad. Sci. U.S.A. 94, 9412-9416.
30. Blume, A.J., and Vitek, M.P. 1989. Focusing on IL-1 promotion of β-amyloid precursor protein synthesis as an early event in Alzheimer's disease Neurobiol. Aging 19, 406-408.
31. Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, P., and Berger, M. 1991. Interleukin-6 and α 2-macroglobulin indicate an acute-phase in Alzheimer's disease. FEBS Lett. 285, 111-114.
32. Fillit, H., Ding, W., Buee, L., Kalman, J., Altstiel, L., Lawlor, B., and Wolf-Klein, G. 1991. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129, 318-320.
33. Del Bo, R., Angeretti, N., Lucca, E., De Simoni, M. G., and Forloni, G. 1995. Reciprocal control of inflammatory cytokines, IL-1 and IL-6 and beta-amyloid production in cultures. Neurosci. Lett. 188, 70-74.
34. Goldgaber, D., Harries, H.W., Hla, T., Maciag, T., Donnelly, R.T., Jacobson, J.S., Vitek, M.P., and Gajdusek, D.C. 1989. Interleukin 1 regulates synthesis of amyloid β-protein precussor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 86, 7608-710.
35. Katsuki, H., Nakai, S., Hirai, Y., Akaji, K., Kiso, Y., and Satoh, M. 1990. Interleukin-1β inhibits long term potentiation in the CA3 region of mouse hippocampal slices. Eur. J. Pharmacol. 181, 323-326.
36. Cavaillon, J.-M., and Fitting, C. 1986. Inhibition of lipopolysaccharide-induced monocyte interleukin-1 secretion by gangliosides. Eur. J. Immunol. 16, 1009-1012.
37. Maeda, L., Cassatella, M.A., Szendrei, G. I., Otvos, L., Baron, P., Villabe, M., Ferrari, D., and Rossi, F. 1995. Activation of microglial cells by β-amyloid protein and interferon-τ. Nature 374, 647-650.
38. Ziehler-Heitbrock, H.E.L., Kafferlein, W., Haas, J.G., Meyer, N., Strobel, M., Weber, C., and Fitting, C. 1992. Gangliosides suppress tumor necrosis factor production in human monocytes. J. Immunol. 148, 1753-1758.
39. Irani, D.N., Lin, K-I., and Griffin, D.E. 1996. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J. Immunol. 157, 4333-4340.
40. Parton, R.G.I. 1994. Ultrastructural localization of gangliosides: GM1 is concentrated in caveola. Histochem. Cytochem. 42, 155-166.
41. Sherrington, R., Rogaev, F.L., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Holman, T., Tsuda, T., Mar, L., Foncin, J-F., Bruni, A.C., Montesi, M.P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, F., Polinski, R.J., Wasco, W., DaSilva, W. A. R., Raines, J.L., Pericak-Venes, M.A., Tranzi, R.F., Roses, A.D., Fraser, P.E., Rommens, J.M., and St. George-Hyslop, P. H. 1995. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 375, 754-760.
42. Goux, W.J., Rodriguez, S., and Sparkman, D.R. 1996. Characterization of the glycolipid associated with Alzheimer paired helical filaments. J. Neurochem. 67, 723-733.
43. Choo-Smith, L-P., and Surewicz, W.K. 1997. The interaction between Alzheimer amyloid β (1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95-98.
44. Choo-Smith, L.-P., Garzon-Rodriguez, W., Glabe, C., and Surewicz, W.K. 1997. Acceleration of amyloid fibril formation by specific binding of Aβ (1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272, 22987-22990.
45. McLaurin, J., Franklin, T., Bergeron, C., Fraser, P.E., and Chakrahartry, A. 1998. Structural transitions associated with the interactions of Alzheimer β-amyloid peptides with gangliosides. J. Biol. Chem. 273, 4506-4515.
46. Katzman, R., and Thal, L. F. 1989. Neurochemistry of Alzheimer's disease. Pages 827-838. in Siegel, G., Agranoff, Albers, R. W., & Molinoff, P. eds., Basic Neurochemistry 4th ed.
47. Takahashi, H., Hirokawa, K., Ando, S., and Obata, K. 1991. Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, c-series gangliosides and microtubule-associated protein 5. Acta Neuropathol. 81, 626-631.
48. Svennerholm, L. 1994. Gangliosides - A new therapeutic agent against stroke and Alzheimer's disease. Life Sci. 55, 2125-2134.
49. Augustinsson, L.-E., Blennow, K., Blomstrand, C., Brane, G., Ekman, R., Fredman, A., Karlsson, I., Kihlgren, M., Lehmann, W., Lekman, A., Mansson, J-E., Ramstrom, I., Wallin, A., Wikkelso, C., Gottfries, C.-G., and Svennerholm, L. 1997. Intracerebroventicular administration of GM1 ganglioside to presenile Alzheimer patients. Dement. Geriatr. Cogn. Disord. 8, 26-33.
50. Mutoh, T., Tokuda, A., Miyada, T., Hamaguchi, M., and Figiki. 1995. N Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. USA. 92, 58087-5091.
51. Farooqui, T., Franklin, T., Pearl, D.K., and Yates, A.J. 1997. Ganglioside GM1 enhances induction by nerve growth factor of a putative dimmer of TrkA. J. Neurochem. 68, 2348-2355.
52. Ferrari, G., Anderson, B.L., Stephens, R.M., Kaplan, D.R., and Greene, L.A. 1995. Prevention of apoptotic neuronal death by GM1 ganglioside. J. Biol. Chem. 270, 3074-3980.